Journal of Equine Veterinary Science
Volume 30, Issue 2 , Pages 79-82 , February 2010

The Pain State Arising From the Laminitic Horse: Insights Into Future Analgesic Therapies

References 

  1. Hood DM, Wagner IP, Taylor DD, Brumbaugh GW, Chan MK. Voluntary limb-load distribution in horses with acute and chronic laminitis. Am J Vet Res. 2001;62:1393–1398
  2. Rietmann TR, Stauffacher M, Bernasconi P, Auer JA, Weishaupt MA. The association between heart rate, heart rate variability, endocrine and behavioural pain measures in horses suffering from laminitis. J Vet Med A Physiol Pathol Clin Med. 2004;51:218–225
  3. Bowker RM, Brewer AM, Vex KB, Guida LA, Linder KE, Sonea IM, et al. Sensory receptors in the equine foot. Am J Vet Res. 1993;54:1840–1844
  4. Moore RM, Eades SC, Stokes AM. Laminitis: which pathway is responsible for initiation of this process in horses?. Equine Vet J. 2004;36:204–209
  5. Bailey SR, Marr CM, Elliott J. Current research and theories on the pathogenesis of acute laminitis in the horse. Vet J. 2004;167:129–142
  6. Lunn DP, Hurley DJ. The role of leukocyte biology in laminitis. Vet Immunol Immunopathol. 2009;129:158–160
  7. Hucho T, Levine JD. Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron. 2007;55:365–376
  8. Coutaux A, Adam F, Willer JC, Le Bars D. Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine. 2005;72:359–371
  9. Svensson CI, Yaksh TL. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol. 2002;42:553–583
  10. D'Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth. 2008;101:8–16
  11. Yaksh TL. Central pharmacology of nociceptive transmission. In:  McMahon SB,  Koltzenburg M editor. Wall and Melzack's textbook of pain. 5th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2006;p. 371–414
  12. Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain. 2006;7(1 Suppl. 1):S13–S30
  13. Jones E, Viñuela-Fernandez I, Eager RA, Delaney A, Anderson H, Patel A, et al. Neuropathic changes in equine laminitis pain. Pain. 2007;132:321–331
  14. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001;429:23–37
  15. Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol. 2004;44:371–397
  16. Price TJ, Cervero F, de Koninck Y. Role of cation-chloride-cotransporters (CCC) in pain and hyperalgesia. Curr Top Med Chem. 2005;5:547–555
  17. Ramer MS, Thompson SW, McMahon SB. Causes and consequences of sympathetic basket formation in dorsal root ganglia. Pain. 1999;(Suppl 6):S111–S120
  18. Inoue K, Tsuda M. Microglia and neuropathic pain. Glia. 2009;57:1469–1479
  19. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10:23–36
  20. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin–calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142:13–16
  21. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004;(Suppl 1):S15–S19
  22. Hans G, Schmidt BL, Strichartz G. Nociceptive sensitization by endothelin-1. Brain Res Rev. 2009;60:36–42
  23. Bermejo PE, Anciones B. Neuromodulators and therapeutic targets in neuropathic pain: from molecules to man. CNS Neurol Disord Drug Targets. 2009;8:175–183
  24. Jarvis MF, Honore P, Shieh CC, Chapman M. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A. 2007;104:8520–8525
  25. Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature. 2007;449:607–610
  26. Kissin I. Vanilloid-induced conduction analgesia: selective, dose-dependent, long-lasting, with a low level of potential neurotoxicity. Anesth Analg. 2008;107:271–281
  27. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev. 2009;60:267–277
  28. Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, et al. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology. 2005;103:1052–1059
  29. Wiley RG. Substance P receptor-expressing dorsal horn neurons: lessons from the targeted cytotoxin, substance P-saporin. Pain. 2008;136:7–10
  30. Allen JW, Mantyh PW, Horais K, Tozier N, Rogers SD, Ghilardi JR, et al. Safety evaluation of intrathecal substance P-Saporin, a targeted neurotoxin, in dogs. Toxicol Sci. 2006;91:286–298

PII: S0737-0806(10)00048-1

doi: 10.1016/j.jevs.2010.01.046

Journal of Equine Veterinary Science
Volume 30, Issue 2 , Pages 79-82 , February 2010

Article Tools